PLAINSBORO, N.J., Sep 16, 2007 (PrimeNewswire via COMTEX News Network) --

Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that Integra NeuroSciences has received 510(k) clearance from the United States Food and Drug Administration to market the DuraGen XS(TM) Dural Regeneration Matrix in the United States.

The DuraGen XS(TM) dural graft is the latest generation in Integra's line of duraplasty materials based on Integra's market leading absorbable collagen matrix technology. Integra launched DuraGen(R) Dural Graft Matrix, the first onlay collagen graft for dural repair, in 1999. This was followed by the launch of DuraGen Plus(R) Dural Regeneration Matrix in 2003. Subsequently, Suturable DuraGen(TM) Dural Regeneration Matrix was brought to market in 2005. Following the 1999 introduction of DuraGen(R), the Integra family of duraplasty materials rapidly became the standard of care for sutureless closure of dural defects in the U.S.A.

"The introduction of DuraGen XS(TM) Dural Regeneration Matrix demonstrates Integra's sustained commitment to providing the neurosurgical community with innovative technology and materials for the management of dural defects. DuraGen XS(TM) has a higher collagen content while maintaining the same porous structure found in our DuraGen Plus(R) materials. The resulting graft is stronger and more robust," said Mark Spilker, Ph.D., Integra's Vice President of Research and Development.

Based on available procedural data, Integra estimates that DuraGen XS(TM) and other DuraGen(R) dural grafts have the potential to be used in over 225,000 neurosurgical procedures annually in the U.S.

The dura mater is a tough, fibrous membrane that surrounds and protects the tissues of the brain and spinal cord. Head and spinal injuries often result in laceration of the dura mater and neurosurgical procedures require the opening or removal of the dura mater to gain access to the delicate tissues contained within. In both cases, effective dural closure is imperative to prevent cerebrospinal fluid leaks and facilitate wound healing. Dural defects may be repaired with dural graft substitutes. The onlay graft technique, possible with Integra DuraGen(R) dural grafts, allows neurosurgeons to conclude operations more efficiently than when using materials that require sutures.

The Integra NeuroSciences organization has one of the largest OR-based neurosurgical sales forces in the U.S. and includes more than 150 sales professionals. Integra NeuroSciences is a leading provider of implants, devices, instruments, and systems used in neurosurgery, neuromonitoring, neuro-trauma, and related critical care.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. The company's products, used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, are used to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and it has research and manufacturing facilities throughout the world. www.Integra-LS.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of the DuraGen XS(TM) Dural Regeneration Matrix Implant and all other DuraGen(R) products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the Risk Factors included in Item lA of Integra's Annual Report on Form 10-K for the year ended December 31, 2006, and information contained in subsequent filings with the Securities and Exchange Commission, could affect actual results.

IART-P

This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation
          John B. Henneman, III, Executive Vice President, 
           Chief Administrative Officer, Acting Chief Financial 
           Officer 
            (609) 936-2481 
            jhenneman@Integra-LS.com 
          Gianna Sabella, Public Relations Manager 
            (609) 936-2389
            gsabella@integra-LS.com

(C) Copyright 2007 PrimeNewswire, Inc. All rights reserved.

News Provided by COMTEX